Toxicity After Central versus Peripheral Lung Stereotactic Body Radiation Therapy: A Propensity Score Matched-Pair Analysis
Author:
Publisher
Elsevier BV
Subject
Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology,Radiation
Reference19 articles.
1. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group;Ginsberg;Ann Thorac Surg,1995
2. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: Updated results of 257 patients in a Japanese multi-institutional study;Onishi;J Thorac Oncol,2007
3. Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer;Grills;J Clin Oncol,2010
4. Lobectomy, Wedge Resection, or Stereotactic Radiotherapy (SBRT) for Stage I Non-small Cell Lung Cancer: Which Treatment Yields the Best Outcome?;Welsh;Int J Radiat Oncol Biol Phys,2010
5. Stereotactic body radiation therapy for inoperable early stage lung cancer;Timmerman;JAMA,2010
Cited by 31 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Optimizing lung cancer radiation therapy: A systematic review of multifactorial risk assessment for radiation-induced lung toxicity;Cancer Treatment Reviews;2024-03
2. Chinese clinical practice guidelines for the prevention and treatment of radiation‐induced esophagitis;Precision Radiation Oncology;2023-09-20
3. Prognostic Factors of Oligometastasis after Stereotactic Body Radiotherapy: Real-world Utility of the European Society for Radiotherapy and Oncology/European Organisation for Research and Treatment of Cancer Classification;2023-08-30
4. A guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation—part 4: systematic review of evidence involving SBRT and ablation;Journal of Thoracic Disease;2022-06
5. Stereotactic radiotherapy for lung oligometastases;Reports of Practical Oncology and Radiotherapy;2022-03-14
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3